Trials / Completed
CompletedNCT02499783
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction and Maintenance of Clinical Remission in Chinese Patients With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 205 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active Crohn's disease in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | subcutaneous injections of adalimumab |
| OTHER | placebo | subcutaneous injections of placebo |
Timeline
- Start date
- 2015-08-17
- Primary completion
- 2017-05-19
- Completion
- 2017-12-15
- First posted
- 2015-07-16
- Last updated
- 2019-01-04
- Results posted
- 2019-01-04
Source: ClinicalTrials.gov record NCT02499783. Inclusion in this directory is not an endorsement.